Our Research and Clinical Trials are being conducted by Dr. Scott A. Waldman, MD, PhD, FCP, FNAI of Thomas Jefferson University in Philadelphia, PA.
Scott A. Waldman, MD, PhD, FCP, FNAI
Dr. Waldman’s career has focused on integrating basic, translational, and clinical research in transmembrane signaling to advance laboratory discovery into patients.
- This work has produced >300 publications (h index=68, >17,000 citations) and >100 patents and patent applications
- Discoveries have been licensed by 7 companies and have been the focus of >15 clinical trials
- Internationally recognized leader in the field of clinical pharmacology
- Editor-In-Chief of Clinical Pharmacology & Therapeutics, Founder and Editor of Biomarkers in Medicine, and Founder and former Deputy Editor-In-Chief of Clinical and Translational Science
- Retired Chair of NCI Subcommittee
- Recently (2019) retired chair of the FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee
- Recurring member of the FDA Oncology Drugs and the Arthritis Drugs Advisory Committee
- Past President of the American Society for Clinical Pharmacology and Therapeutics, a former Regent of the American College of Clinical Pharmacology, and the former Secretary/Treasurer of the American Board of Clinical Pharmacology
- Institutionally, Director of the KCC Gastrointestinal (GI) Malignancies Program, the MD-PhD Program, and the Postdoctoral Training Program in Clinical Pharmacology (5T32 GM08562)
- Chairman (tenured), Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA
- MD, Stanford University
- PhD, Thomas Jefferson University
The discovery of GCC expression as a unique biomarker for detecting metastatic colorectal cancer has led to the development of the GCC Cancer Vaccine and GCC CAR-T cell therapeutics.
Click below to learn more to read about the clinical trials for these potential breakthrough therapies.
|GCC Cancer Vaccine||GCC CAR-T|
|FDA phase I clinical trial complete; currently preparing for FDA phase IIa clinical trial||Preclinical trials completed; preparations for FDA phase I clinical trial are underway|
Phase I Trial
Phase II Trial Design
Phase I Trial